Adam Lezack Sells 998 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Adam Lezack sold 998 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $11.21, for a total value of $11,187.58. Following the completion of the transaction, the director directly owned 27,399 shares of the company’s stock, valued at $307,142.79. This represents a 3.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adam Lezack also recently made the following trade(s):

• On Thursday, May 21st, Adam Lezack sold 1,000 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total value of $9,950.00.

Beta Bionics Stock Performance

Shares of NASDAQ:BBNX opened at $11.63 on Thursday. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The firm has a market capitalization of $518.23 million, a P/E ratio of -7.70 and a beta of 3.29. The stock has a 50 day moving average price of $10.66 and a 200-day moving average price of $17.83.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The firm had revenue of $27.63 million during the quarter. On average, equities analysts forecast that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Robert W. Baird reduced their price objective on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. UBS Group raised Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Leerink Partners reduced their price objective on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Finally, Stifel Nicolaus reduced their price objective on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GPS Wealth Strategies Group LLC increased its position in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Beta Bionics by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after purchasing an additional 931 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Beta Bionics by 3.4% in the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock worth $1,197,000 after purchasing an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Beta Bionics in the 4th quarter worth $52,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.